After rising in premarket trading, Novo Nordisk's (NVO) U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weight-loss drugs Ozempic and Wegovy.

The Danish drugmaker reported 71.31 billion Danish krone ($10.24 billion) in sales—a 21% jump from the same time last year—but still just below the DKK 72.17 billion ($10.36 billion) analysts had expected, according to estimates compiled by Visible Alpha. Despite the sales miss, Novo Nordisk's net income of DKK 27.3 billion came in higher than the DKK 26.66 billion analysts were expecting.

Sales of the company's obesity and diabetes drugs jumped 25% from the same time last year, while sales in North America surged 31% in the quarter. The company has faced questions from U.S. lawmakers about why its products are so much more expensive in the U.S. thanEuropean countries.

"The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before," Novo Nordisk CEO Lars Fruergaard Jørgensen said.

The company also narrowed its full-year guidance, projecting sales growth between 23% to 27%, with both the high and low end slightly narrower than the 22% to 28% projected growth previously. The same adjustment was made to operating profit projections, as Novo Nordisk now expects the metric to grow 21% to 27% year-over-year, compared to the previous range of20% to 28%.

Novo Nordisk's U.S.-traded shares were down 3% in morning trading Wednesday.

Read more on Investopedia

Shares in Super Micro Computer (SMCI) tumbled in extended trading Tuesday after the troubled server maker provided preliminary fiscal first-quarter results that came in below Wall Street expectations and said it’s unable to predict when it will file its delayed 2024 annual report.

Tuesday’s updates follow a turbulent period for the company, which last week saw its shares plunge around 45% after its auditor, Big Four accounting firm EY, resigned. That move came as speculation continues to mount over corporate governance challenges facing Super Micro amid allegations of accounting abnormalities

Super Micro Computer shares fell 16% to $23.30 in after-hours trading Tuesday. The stock, once an up-and-coming artificial intelligence (AI) favorite that hit a high around $123 in March, was down slightly year-to-date through Tuesday's close.

Below, we take a closer look at the technicals on Super Micro Computer’s weekly chart and point out major price levels to watch out for. 

After trading within a six-month falling wedge, Super Micro Computer shares broke down below the pattern late last month.

Importantly, the move occurred on the highest weekly volume since late August, suggesting strong selling conviction among larger market participants, such as institutional investors and hedge funds.

Despite an early-November bounce, the stock sits poised to test lower levels again on Wednesday following the company’s latest updates.

Let’s identify several crucial support levels and a key resistance area on Super Micro’s chart that investors may be watching.

Firstly, it’s worth keeping an eye on the $23 level. This key location on the chart finds a confluence of support near the 200-week moving average and a trendline linking the lower level of a period of consolidation in the stock between May and October last year.

A decisive breakdown below this level opens the door for a move down to around $12, where the shares could attract buying interest near a series of highs in March and April last year that formed as part of the stock’s impulsive move higher from January to July.

Further selling could see the stock revisit lower support near $10, an area around 64% below Tuesday’s closing price where buy-and-hold investors may seek entries around a range of comparable trading levels that formed on the chart between November 2022 and April last year.

Upon an upswing, investors should monitor the $30 area. Investors who have purchased the stock at lower levels may look to lock in profits near a trendline that connects the top of a prior trading range on the chart from August 2023 to early January this year.

Read more on Investopedia